Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Adrenocortical disorders

810 views

Published on

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

Adrenocortical disorders

  1. 1. Acquired  Autoimmune  AIDS  Tuberculosis  Bilateral injury ◦ Hemorrhage ◦ Necrosis ◦ Metastasis  Idiopathic  Iatrogenic Congenital  Congenital adrenal hypoplasia Syndromes  Autoimmune polyglandular syndrome 1. APS1 2. APS2
  2. 2. Decrease function Increase function  Adrenal insufficiency  CAH  Low cortisol, aldestrone Addison disease  Cushing syndrome High Cortisol  Hyperaldosteronism High aldestrone  CAH  Pheochromocytoma High catecholamine .
  3. 3.  Glucocorticoids are essential for life and have mutiple pysiological effects.  Metabolic actions include enhanced gluconeogenesis and inhibition of peripheral glucose utilization.  Glucocorticoids are required for vascular and bronchial smooth muscle to be responsive to catecholamines.  Glucocorticoids are structurly related to aldosterone, so they have aldosterone like action.
  4. 4.  ACTH is the principal regulator of Glucocorticoids secretion.  Secretion of ACTH and glucocorticoids exhibit a diurnal rhythm, stimulated by stress and inhibited by circulating glucocorticoids.  Endogenous production of cortisol averages 20 mg day.
  5. 5. Mineralocorticoid excess  I- Primary hyperaldosteronism (Conn syndrome):  Conn syndrome is characterized by increased aldosterone secretion from the adrenal glands, it was first described in 1955 by J. W. Conn in a patient who had an aldosterone-producing adenoma.
  6. 6.  Pathophysiology  Primary hyperaldosteronism is caused by increased aldosterone excretion from the adrenals, which results primarily from 2 major subtypes:  (1) unilateral aldosterone-producing adenoma , Conn syndrome, (50-60% of cases) (2) idiopathic hyperaldosteronism (IHA) or bilateral adrenal hyperplasia (40-50% of cases). (3) Rarely, aldosterone can be secreted by adrenocortical carcinomas and ovarian tumors.
  7. 7.  Aldosterone, by inducing renal distal tubular reabsorption of sodium, enhances secretion of potassium and hydrogen ions, causing hypernatremia, hypokalemia.
  8. 8. Conn syndrome, is primarily related to;  1- Hypertension, especially if left untreated for many years, can lead to many complications, including heart disease (eg, coronary artery disease, congestive heart failure), stroke, and intracerebral hemorrhage (with very high blood pressure).  2-Hypokalemia, especially if severe, causes cardiac arrhythmias, which can be fatal.
  9. 9.  II- Secondary hyperaldosteronism:  There is increased renin-angiotensin with increased aldosteron secretion;  Causes:  -CHF  -Liver cirrhosis and ascitis  -Nephrotic syndrome  -Renal artery stenosis
  10. 10. Clinical manifestations  -Hypertension;  -Hypokalemia;  patients with severe hypokalemia report fatigue, muscle weakness, cramping, headaches, and palpitations. They can also have polydypsia and polyuria from hypokalemia induced nephrogenic diabetes insipidus.  -Metabolic alkalosis; will lower ionized calcium levels and can cause tetany. 
  11. 11.  Investigations:  Laboratory Studies  Hypernatremia  Hypokalemia; normokalemia does not exclude primary hyperaldosteronism. Several studies have shown that 7-38% of patients with primary hyperaldosteronism have normal baseline serum levels of potassium
  12. 12.  metabolic alkalosis  Renin levels are suppressed to less than 1 ng/mL/h in patients with primary hyperaldosteronism.  A 24-hour aldosterone excretion rate of greater than 14 ug is diagnostic of primary hyperaldosteronism
  13. 13.  Imaging Studies  -CT scanning  -MRI
  14. 14.  Treatment  Medical  medical therapy is used preoperatively to prevent the morbidity and mortality associated with hypertension and hypokalemia, thus decreasing surgical risk.  Sodium-restricted diet (<80 mEq or <2 g of sodium per day.  Potassium-sparing agent (first-step agent) such as spironolactone100 mg initially, increase to 400 mg/d for control of blood pressure.
  15. 15.  Potassium supplementation should not be routinely administered with spironolactone because of the potential for the development of hyperkalemia.  Second-step agents include thiazides diuretics, ACE inhibitors, calcium channel antagonists, and angiotensin II blockers.
  16. 16.  Mineralocorticoid deficiency  Hypo-aldosteronism  Atrophy or destruction of both adrenal glands results in a combined deficiency of Mineralocorticoid and glucocorticoid ( addison disease) .  Isolated Mineralocorticoid deficiency;  Unilateral adrenalectomy  Congenital
  17. 17.  CP  *Hypotension; due to hypovolemia  *Metabolic acidosis  *Hyperkalemia; any increase in Sr. potassium without renal impairment, hypoaldosteronism should be considered.  *hyponatremia
  18. 18.  Glucocorticoid excess  Cushing syndrome  Cushing syndrome is caused by prolonged exposure to elevated levels of either endogenous glucocorticoids or exogenous glucocorticoids
  19. 19.  Causes:  Exogenous steroid administration Symptoms of glucocorticoid excess generally occur with the administration of oral steroids; however, occasionally injections of steroids into joints and the use of steroid inhalers can cause Cushing syndrome. 
  20. 20.  Patients at risk to develop cushing syndrome includes:  rheumatological, pulmonary, neurological, and nephrologic diseases that respond to steroid therapy.  Patients who have undergone organ transplants due to exogenous steroids required as part of graft antirejection medication regimens.
  21. 21.  Endogenous glucocorticoid administration  ACTH-producing pituitary adenoma ( Cushing disease).  Primary adrenal lesions; Overproduction of glucocorticoids may be due to an adrenal adenoma, adrenal carcinoma, or macronodular or micronodular adrenal hyperplasia.  Ectopic ACTH is sometimes secreted by oat cell or small-cell lung tumors or by carcinoid tumors.
  22. 22.  Amino acid catabolism (muscle wasting)… gluconeogenesis in the liver.. Hyperglycemia… increased insulin output… eventual beta cell failure… fat deposition… diabetes  Ca resorption, impairment of Ca absorbtion, increased renal Ca excretion…. osteoporosis  Increased gastric acidity… ulcer formation or aggravation  K loss and Na retention… edema and hypertension  Initially increased antibody release.. Eventually decreased antibody production, lymphocytopenia, eosinopenia, neutrophelia, polycythemia… susceptibility to infections  Maintenance of arteriolar tone and blood pressure
  23. 23. Obesity -moon facies -buffalo hump -Central obesity, increased waist-to-hip ratio greater than 1 in men and 0.8 in women
  24. 24. Skin Facial plethora abdominal striae facial hair Hirsutism and Steroid acne
  25. 25. Cardiovascular and renal Hypertension and possibly edema may be present due to cortisol activation of the mineralocorticoid receptor leading to sodium and water retention Gastroenterologic Peptic ulceration may occur with or without symptoms.
  26. 26. endocrine Galactorrhea and menstrual disturbances decreased libido and impotence in men. Skeletal/muscular Proximal muscle weakness Osteoporosis and osteopenia Avascular necrosis of the hip
  27. 27. Neuropsychological emotional liability, fatigue, and depression
  28. 28.  Investigations  Laboratory Studies  Hyperglycemia  Hypokalemic metabolic alkalosis Biochemical evaluation of Cushing syndrome:  1-Urinary free cortisol excretion over 150 ug day.
  29. 29.  2- dexamethasone suppression test; glucocorticoids inhibit secretion of hypothalamic CRH and pituitary ACTH but do not directly affect adrenal cortisol production. The overnight 1-mg dexamethasone suppression test requires administration of 1 mg of dexamethasone at 11 PM with subsequent measurement of cortisol level at 8 am. In healthy individuals, the serum cortisol level should be less than 2-3 ug/dL.
  30. 30.  3-loss of circadian rhythm of cortisol secretion  Normal values, 10-25 ugml in the morning, 2-10 ugml in the evening, elevated serum cortisol at 11 PM can be an early finding.  Recently, measuring salivary cortisol level has gained interest, as it is a simple and convenient way of obtaining a night time sample. Levels less than 1.3-1.5 ng/mL exclude Cushing syndrome. 
  31. 31.  4- A plasma ACTH of less than 5 pg/mL is suggestive of a primary adrenal tumor. An ACTH level greater than 10-20 pg/mL is consistent with ACTH-dependent Cushing syndrome.  Imaging studies CT or MRI brain and abdomen
  32. 32.  Pathophysiology Addison disease is adrenocortical insufficiency due to the destruction or dysfunction of the entire adrenal cortex. It affects glucocorticoid and mineralocorticoid function. The onset of disease usually occurs when 90% or more of both adrenal cortices are dysfunctional or destroyed.
  33. 33.  Causes  1- idiopathic  2- Chronic granulomatous diseases; TB, histoplasmosis.  3- Hematologic malignancies; Hodgkin and non-Hodgkin lymphoma and leukemia.
  34. 34. 4- Metastatic malignant disease; as metastatic cancer of the lung, breast, colon or renal cell carcinoma.  5-Infiltrative metabolic disorders; Amyloidosis and hemochromatosis.  6- AIDS.
  35. 35.  Secondary adrenal insufficiency is a result of inadequate ACTH secretion by the pituitary, the most common cause of secondary adrenal insufficiency is iatrogenic, the result of the administration of exogenous glucocorticoids.
  36. 36.  CP  Patients usually present with features of both glucocorticoid and mineralocorticoid deficiency. The predominant symptoms vary depending on the duration of disease.  -Hyperpigmentation of the skin and mucous membranes due to high ACTH.  - vitiligo, which most often is seen in idiopathic autoimmune Addison disease.
  37. 37.  -clinical manifestations due to cortisol deficiency; weakness, fatigue, hypoglycemia, hypotension, and weight loss.  -Prominent gastrointestinal symptoms may include nausea, vomiting, and occasional diarrhea.  - Patients with secondary insufficiency have a history of taking cortisol.  clinical manifestations due to aldosterone deficiency; hyponatremia, hypovolemia, hypotension, hyperkalemia.
  38. 38.  Investigations  Laboratory Studies  -ACTH stimulation test; In patients with Addison disease, both cortisol and aldosterone show minimal or no change in response to ACTH.  Hyponatremia  Hyperkalemia
  39. 39.  elevated (BUN) and creatinine due to the hypovolemia with decreased glomerular filtration rate.  Hypoglycemia  adrenal autoantibodies may be present
  40. 40.  Imaging study  Chest x-ray TB  CT abdomen
  41. 41. .
  42. 42.  Congenital adrenal hyperplasia (CAH) is a general term used to describe a group of inherited disorders in which a defect in cortisol biosynthesis is present with consequent overproduction of (ACTH) and secondary adrenal hyperplasia as a consequence.
  43. 43.  Patients with 11-beta-hydroxylase deficiency present with features of androgen excess, including masculinization of female newborns and precocious puberty in male children.  Approximately two thirds of patients also have hypertension, which may or may not be associated with mineralocorticoid excess, hypokalemia, hypernatremia and metabolic alkalosis.
  44. 44.  The hypertension is initially responsive to glucocorticoid replacement, but it may become a chronic condition subsequently requiring standard antihypertensive therapy.
  45. 45.  Ambiguous genitalia in girls  Hyperpigmentation  Dehydration  Salt-loss presentations with electrolytes imbalance ◦ Hyponatremia ◦ Hyperkalaemia  Hypoglycemia  Shock
  46. 46. Are unrecognized at birth because their genitalia are normal.  Present early with salt wasting crisis resulting in dehydration, hypotension, hyponatremia and hyperkalemia Or present later in childhood with early pubic hair, precocious puberty and accelerated growth
  47. 47. Neural Crest Sympathoadrenal Progenitor Cell (Neuroblasts) Chromaffin Cell Sympathetic Ganglion Cell Intra-adrenal Extra-adrenal Pheochromocytoma Ganglioneuroma Neuroblastoma
  48. 48.  Pheochromocytoma  Paraganglioma (extra-adrenal pheo)  Originate in extra-adrenal sympathetic chain/chromaffin tissue  Ganglioneuroma  Behave like paraganglioma biochemically
  49. 49.  Neuroblastoma  Common malignancy in children, adrenal or sympathetic chain.  Rapid growth & widespread metastasis  Some differentiate and spontaneously regress  Rx complex (surgery, RT, chemotherapy)  Cheodectoma  Carotid body, behave like paraganglioma biochemically  Glomus jugulare tumor  Intracranial branch of CN IX and X  Behave like paragangliomoa biochemically
  50. 50.  Neuroendocrine tumour of the medulla of the adrenal glands  Originates from the chromaffin cells along the paravertebral sympathetic chain extending from pelvis to base of skull  >95% are abdominal  >90% in adrenal medulla  Secretes excessive amounts of adrenaline and noradrenaline  80% occur unilateral
  51. 51.  10% extra-adrenal (closer to 15%)  10% occur in children  10% familial (closer to 20%)  10% bilateral or multiple (more if familial)  10% recur (more if extra-adrenal)  10% malignant  10% discovered incidentally
  52. 52. Tyrosine L-Dopa Dopamine Norepinephrine Epinephrine Catecholamines Normetanephrine Metaneprine PNMT DBH COMT COMT Metabolites Homovanillic acid (HVA) MAO, COMT Vanillymandelic Acid (VMA) MAO MAO TH
  53. 53.  Alpha-Adrenergic Receptors  α1: vasoconstriction, intestinal relaxation, uterine contraction, pupillary dilation  α2: ↓ presynaptic NE (clonidine), platelet aggregation, vasoconstriction, ↓ insulin secretion  Beta-Adrenergic Receptors  β1: ↑ HR/contractility, ↑ lipolysis, ↑ renin secretion  β2: vasodilation, bronchodilation, ↑ glycogenolysis  β3: ↑ lipolysis, ↑ brown fat thermogenesis
  54. 54.  0.01-0.1% of HTN population  Found in 10% of those screened  M = F  3rd to 10th decades of life  Rare, investigate only if clinically suspicion:  Signs or Symptoms  Severe HTN, HTN crisis  Refractory HTN (> 4drugs)  Adrenal lesion found on imaging (ex. Incidentaloma)
  55. 55.  The five P’s:  Pressure (HTN)9%  Pain (Headache) 80%  Perspiration 71%  Palpitation 64%  Pallor 42%  Paroxysms (the sixth P)  The Classical Triad:  Pain (Headache), Perspiration, Palpitations  Lack of all 3 virtually excluded diagnosis of pheo in a series of > 21,0000 patients
  56. 56. Diagnosis 1. Biochemical 2. Localization
  57. 57. Positive results (> 2-3 fold elevation):  24h Ucatechols > 2-fold elevation  ULN for total catechols 591-890 nmol/d  24h Utotal metanephrines > 1.2 ug/d (6.5 umol/d)  24h UVMA > 3-fold elevation  ULN 35 umol/d for most assays  Detected by high performance liquid chromatography
  58. 58.  Test Characteristics:  24h urinary catechol Sen 83% Spec 88%  24h U total metanephrines Sen 76% Spec 94%  24h Ucatechols + Utotal metanephrines Sen 90% Spec 98%  24h UVMA Sen 63% Spec 94%  Sensitivity increased if 24h urine collection begun at onset of a paroxysm  Serum creatinine measured for all collections of urine to determine adequacy of collection
  59. 59.  Plasma free metanephrines sen 99% spec 89%  Plasma catecholamines sen 84% spec 81%

×